Navigation Links
Human neural stem cells could meet the clinical problem of critical limb ischemia
Date:11/25/2013

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia (CLI) is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

The study, led by academics in the University of Bristol's School of Clinical Sciences, is published online in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Current stem cell therapy trials for the treatment of CLI have revitalised new hope for improving symptoms and prolonging life expectancy. However, there are limitations on the use of autologous cell therapy. The patient's own stem cells are generally invasively harvested from bone marrow or require purification from peripheral blood after cytokine stimulation. Other sources contain so few stem cells that ex vivo expansion through lengthy bespoke Good Manufacturing Practice processes is required. Ultimately, these approaches lead to cells of variable quality and potency that are affected by the patient's age and disease status and lead to inconsistent therapeutic outcomes.

In order to circumvent the problem a team, led by Professor Paolo Madeddu in the Bristol Heart Institute at the University of Bristol, has used a conditionally immortalised clonal human neural stem cell (hNSC) line to treat animal models with limb ischaemia and superimposed diabetes. The CTX cell line, established by stem cell company ReNeuron, is genetically modified to produce genetically and phenotypically stable cell banks.

Results of the new study have shown that CTX treatment effectively improves the recovery from ischaemia through the promotion of the growth of new vessels. The safety of CTX cell treatment is currently being assessed in disab
'/>"/>

Contact: Joanne Fryer
joanne.fryer@bristol.ac.uk
44-011-733-17276
University of Bristol
Source:Eurekalert

Page: 1 2

Related medicine news :

1. GHS Cancer Institute and USC School of Medicine Partner on Nation’s First Human Performance Lab to Tackle Cancer Fatigue
2. Research paves path for hybrid nano-materials that could replace human tissue or todays pills
3. HUMAN Ranks #7 on Los Angeles Business Journal’s “Fastest Growing Private Companies” List with Three-Year Sales Growth of 514%
4. 2 human proteins found to affect how jumping gene gets around
5. Diet Doc Hormone Diets & Weight Loss Plans Improve Human Heart Health With Prescription Hormone Diet Plans That Help Dieters Lose Weight Fast
6. What composes the human heart? U of T researchers crunch the numbers
7. Predicting human body height from DNA
8. The human health costs of losing natural systems: Quantifying Earths worth to public health
9. China Human Vaccine Industry Report, 2012-2015
10. Mahendra Trivedi Announces the New Master During the Historical Event “Transforming Humanity”
11. NHS Human Services Foundation to Host 10th Annual Leading the Way Awards Gala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Cook For Your Life (CFYL), a New ... to people touched by cancer, is launching its first ... by founder Ann Ogden, will be facilitated by Drexel ... partnership will expand the program from its base. , ... After going through her own cancer treatments, Ogden realized ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
(Date:3/4/2015)... Surrey, BC (PRWEB) March 04, 2015 ... will perform LASIK and PRK procedures at their new ... Vision Correction, Dr. Joseph King and Dr. Gabriel Chu ... ophthalmology practice in Surrey is named Fraser Valley Cataract ... facility is accredited by the College of Physicians and ...
(Date:3/4/2015)... NY (PRWEB) March 04, 2015 The ... centerfold of The San Francisco Chronicle with a circulation ... 500,000 readers. Its digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... , Milorganite is composed of heat-dried microbes ...
(Date:3/4/2015)... Texas (PRWEB) March 04, 2015 ... , Endometriosis can be a painful condition ... starts spreading outside of the uterus leading to very ... their families. Endometriosis can have a terrible effect on ... It is also the most common cause of infertility ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3
... a discovery that may well be giving HIV health care workers ... men having a highly drug resistant form of HIV in King ... rapidly than others and is likewise more difficult to treat. ... present in the four men, all gay, who are also methamphetamine ...
... the Intensive Care Unit (ICU) and family members of ... and depression in the family members, according to a ... of the New England Journal of Medicine. ... Institute of Nursing Research (NINR), a component of the ...
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... women’s menstrual cycles affect the responsiveness of their brains’ ... of// Mental Health (NIMH), a component of the National ... ,While women were winning rewards, their circuitry was more ... ovulation and dominated by estrogen, compared to a phase ...
... genes from an ancient wheat variety have led to a ... a recent set of papers published in the journal Plant ... and Nax2. The genes work by excluding salt from different ... from the leaves. The discovery of the two genes is ...
... grant product patent for Glivec, the cancer drug from Novartis ... not be able to conduct// their drug research here in ... its research now. ,While talking ... of Novartis reveals that this decision by the Indian government ...
Cached Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:Researchers Make Strides in VCJD Detection 2Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2
(Date:3/4/2015)... , March 4, 2015  Hill-Rom Holdings, Inc. ... Stacy Enxing Seng has been elected to its ... Executive in Residence for Covidien, as well as President ... President of Peripheral Vascular from 2010 to 2012. ... the $2.6B acquisition of ev3 Incorporated, where she was ...
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3
... , , , , ... Inc. (Nasdaq: RIGL ) today announced that in the ... had failed to respond to at least one biologic treatment, the ... ACR 20, ACR 50, ACR 70 and DAS28 response rates than ...
... , G rowth ... for cardiac stem cells , ... regrow, but researchers at Children,s Hospital Boston have now laid the groundwork for ... in children with congenital heart defects. In the July 24 issue of ...
Cached Medicine Technology:R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 8Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
... stents that save inventory, shelf space, and ... lengths from 22 cm to 28 cm. ... to glide over any guidewire and through ... ease of placement and patient comfort in ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run...
Medicine Products: